Welcome to our dedicated page for BridgeBio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BridgeBio Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BridgeBio Pharma's regulatory disclosures and financial reporting.
BridgeBio Pharma Director Fred Hassan received new equity compensation grants on June 20, 2025, consisting of:
- 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total direct ownership to 25,889 shares
- 8,425 Stock Options with an exercise price of $41.73 and expiration date of June 19, 2035
Both grants follow a 3-year vesting schedule with one-third vesting each year starting June 20, 2025, and completing on June 20, 2028. Vesting is contingent on Hassan's continued service as a director. The awards were granted under the company's 2021 Amended and Restated Stock Option and Incentive Plan. This Form 4 filing was signed on June 24, 2025, within the required reporting window.
BridgeBio Pharma Director Douglas A. Dachille reported multiple equity transactions on June 20, 2025:
- Received 6,589 restricted stock units (RSUs) with $0 exercise price, vesting over three years through June 20, 2028
- Granted 8,425 stock options with strike price of $41.73, vesting over three years and expiring June 19, 2035
- Currently holds 20,000 shares indirectly through The Dachille 2012-1 Family Trust for his children's benefit
All equity grants are subject to continued service on BridgeBio's board of directors. The RSUs and options will vest in three equal annual installments starting June 20, 2025. These grants appear to be part of the company's standard director compensation under their 2021 Amended and Restated Stock Option and Incentive Plan.
BridgeBio Pharma Director Hannah Valantine reported multiple equity transactions on June 20, 2025:
- Received 6,589 Restricted Stock Units (RSUs) at $0 cost, vesting over three years through June 20, 2028
- Granted 8,425 stock options with strike price of $41.73, exercisable until June 19, 2035
- Options and RSUs vest in three equal annual installments starting June 20, 2025
Following these transactions, Valantine's holdings include:
- Direct ownership: 8,353 common shares and 8,425 stock options
- Indirect ownership: 3,433 shares held by spouse
These grants appear to be part of standard director compensation under the company's 2021 Amended and Restated Stock Option and Incentive Plan. All vesting is contingent on continued board service.
BridgeBio Pharma Director Randal W. Scott reported significant equity compensation grants on June 20, 2025. The transactions include:
- 6,589 Restricted Stock Units (RSUs) granted at $0, vesting over three years through June 20, 2028
- 8,425 Stock Options awarded with an exercise price of $41.73, vesting over three years through June 20, 2028
Following these transactions, Scott's holdings include 11,589 shares held directly and 4,000 shares held indirectly through Thinking Bench Capital LLC. Both the RSUs and stock options are subject to continued service on the board of directors. The grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan, representing standard director compensation arrangements.
BridgeBio Pharma, Inc. (BBIO) – Form 144 notice of proposed sale
This filing informs the SEC of an intended insider sale under Rule 144:
- Securities: Common Stock
- Shares to be sold: 100,000
- Aggregate market value: $4,422,803.30
- Portion of outstanding: ≈0.05% of the 189,880,720 shares outstanding
- Broker: Merrill Lynch, 555 California St, 18th Fl, San Francisco, CA 94104
- Planned sale date: 24 Jun 2025 on Nasdaq
- How acquired: 200,000-share stock bonus received 1 Oct 2021 from BridgeBio Pharma
- No sales by the filer during the past three months.
The signer attests that no undisclosed material adverse information is known. The notice authorises—but does not require—sales within the next 90 days.
BridgeBio Pharma, Inc. filed a Form 8-K reporting corporate documentation updates. The filing lists a Certificate of Amendment to the Amended and Restated Certificate of Incorporation and the Second Amended and Restated 2021 Stock Option and Incentive Plan with form award agreements as exhibits. The cover page identifies the company, ticker (BBIO), Nasdaq listing and corporate contact details. The document includes an interactive data file reference and is signed by the company’s Chief Legal Officer and Secretary.